Medtronic PLC $MDT Shares Acquired by Lmcg Investments LLC

Lmcg Investments LLC increased its position in shares of Medtronic PLC (NYSE:MDT) by 18.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 136,152 shares of the medical technology company’s stock after purchasing an additional 21,269 shares during the quarter. Lmcg Investments LLC’s holdings in Medtronic were worth $11,749,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in MDT. Petredis Investment Advisors LLC boosted its holdings in Medtronic by 0.4% in the third quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock worth $2,275,000 after purchasing an additional 114 shares during the period. Arlington Trust Co LLC raised its holdings in shares of Medtronic by 11.6% during the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after purchasing an additional 120 shares during the period. Bigelow Investment Advisors LLC raised its holdings in shares of Medtronic by 1.1% during the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock worth $964,000 after purchasing an additional 121 shares during the period. Bank & Trust Co raised its holdings in shares of Medtronic by 2.8% during the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock worth $342,000 after purchasing an additional 121 shares during the period. Finally, Grove Bank & Trust raised its holdings in shares of Medtronic by 1.2% during the third quarter. Grove Bank & Trust now owns 10,564 shares of the medical technology company’s stock worth $912,000 after purchasing an additional 124 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Insider Transactions at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Marinaro sold 10,420 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares in the company, valued at approximately $10,167,936. This trade represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 61,903 shares of company stock worth $5,889,203. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MDT. Stifel Nicolaus raised their price target on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. Barclays raised shares of Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Evercore set a $105.00 price objective on shares of Medtronic in a research note on Monday, July 6th. Finally, UBS Group reissued a “cautious” rating on shares of Medtronic in a report on Wednesday, October 14th. Eighteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $102.88.

Medtronic Price Performance

Shares of MDT opened at $93.05 on Thursday. The company has a market cap of $119.02 billion, a P/E ratio of 22.92, a PEG ratio of 2.21 and a beta of 0.55. The stock has a fifty day moving average price of $91.23 and a 200 day moving average price of $85.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period last year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were given a dividend of $0.72 per share. The ex-dividend date was Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is currently 70.94%.

About Medtronic

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.